6 min learnNew DelhiAug 20, 2026 03:00 PM IST
What if a most cancers drug may stay inactive whereas travelling by way of the physique and swap on primarily when it reaches a most cancers cell? That’s the thought behind RK-251, a brand new experimental most cancers drug developed by researchers in India.
The Ministry of Science & Know-how has shared particulars of the drug, which is designed to use a function of most cancers cells: they usually have greater ranges of reactive oxygen species (ROS), molecules that may be dangerous when current in extra. Researchers have used this distinction to create a drug that may be activated preferentially inside most cancers cells.
The method may doubtlessly make most cancers therapy extra selective and scale back harm to wholesome cells. ”
“A brand new ‘good’ most cancers drug designed to modify on and work solely inside most cancers cells can substitute conventional chemotherapy, which in lots of instances additionally harms wholesome cells. In preclinical research, RK-251 confirmed sturdy exercise in opposition to aggressive triple-negative breast most cancers cells, with a lot much less impact on wholesome cells. The behavioral research of the developed candidate drug in zebrafish embryos (Danio rerio) additionally confirmed no apparent indicators of toxicity and exhibited the specified fluorescence within the presence of reactive oxygen species (ROS), suggesting the drug could also be protected for additional analysis and validation. Extra research are wanted earlier than this expertise will be examined in sufferers. The work is printed in ACS- Journal of Medicinal Chemistry,” the ministry stated in a press assertion.
So what does the brand new ‘good’ most cancers drug imply for us proper now?
DISCLAIMER: This text is predicated on data from the general public area and/or the specialists we spoke to. At all times seek the advice of your well being practitioner earlier than beginning any routine.
How does RK-251 work?
RK-251 was developed by way of a collaboration led by Dr Asis Bala from the Institute of Superior Examine in Science and Know-how (IASST), an autonomous institute beneath the Division of Science & Know-how, and Dr Ok.P. Bhabak from the Indian Institute of Know-how-Guwahati.
Story continues beneath this advert
When RK-251 enters a most cancers cell with excessive ROS ranges, these molecules set off the drug’s activation, releasing an anticancer compound referred to as NBDHEX.
NBDHEX blocks goal proteins that many most cancers cells use to outlive and resist therapy. The thought is to maintain RK-251 comparatively inactive in regular tissues and activate its anticancer motion inside most cancers cells.
May this scale back chemotherapy-related harm?
It’s too early to explain it as a substitute for chemotherapy, as effectiveness and security in people are but to be established (Ai picture)
Conventional cancer treatment can have an effect on wholesome cells together with most cancers cells, contributing to negative effects. A therapy that may distinguish between the 2 extra selectively may doubtlessly scale back this downside.
Dr Siddhesh Trymbake, Advisor Medical & Radiation Oncologist at TGH Onco Life Most cancers Centre, Talegaon, tells indianexpress.com that the method is promising however nonetheless at an early stage.
Story continues beneath this advert
“RK-251 is an fascinating early-stage growth as a result of its mechanism goals to focus on most cancers cells in another way from typical chemotherapy. Nevertheless, it’s far too early to explain it as a substitute for chemotherapy, as effectiveness and security in people are but to be established.”
The ROS-based method may doubtlessly enhance therapy selectivity, however most cancers biology is advanced and the drug’s skill to spare wholesome tissue must be demonstrated by way of additional research.
“The ROS-based method may doubtlessly enhance therapy selectivity by exploiting a organic distinction between most cancers and regular cells. Nevertheless, most cancers biology is advanced, and reaching ample selectivity with out affecting wholesome tissues stays a significant problem that can should be demonstrated by way of additional research.”
What did the early research discover?
➜ A brand new “good” most cancers drug designed to modify on and work solely inside most cancers cells can substitute conventional chemotherapy, which in lots of instances additionally harms wholesome cells.
➜ Most cancers therapy usually damages wholesome cells together with most cancers cells, inflicting important related… pic.twitter.com/LO4R4B0oYU
— PIB India (@PIB_India) August 19, 2026
In preclinical research, RK-251 confirmed sturdy exercise in opposition to aggressive triple-negative breast most cancers cells, with a lot much less impact on wholesome cells.
Researchers additionally studied the candidate drug in zebrafish embryos (Danio rerio). The embryos confirmed no apparent indicators of toxicity beneath the situations examined. The drug additionally displayed the anticipated fluorescence within the presence of ROS, supporting the proposed ROS-responsive activation mechanism.
Story continues beneath this advert
“However these are preclinical findings. The drug has not but been examined in most cancers sufferers. The most important hurdles are establishing security, acceptable dosing, drug behaviour within the human physique and whether or not the therapy can produce significant tumour responses. Outcomes from most cancers cells and zebrafish are encouraging for additional analysis, however they can not predict with certainty how the drug will carry out in precise sufferers,” Dr Trymbake says,
Earlier than RK-251 will be thought of to be used in sufferers, researchers might want to set up its security, decide an acceptable dose, perceive the way it behaves within the human physique and discover out whether or not it will probably produce significant tumour responses.
May it will definitely substitute chemotherapy?
Not essentially.
Even when human trials ultimately present that RK-251 is protected and efficient, it might extra doubtless develop into an alternative choice in most cancers therapy slightly than utterly substitute chemotherapy.
Story continues beneath this advert
“If human trials ultimately present clear advantages, RK-251 would extra doubtless develop into one other instrument within the oncology therapy armamentarium slightly than utterly substitute chemotherapy. Relying on the most cancers sort and affected person profile, it may doubtlessly be studied as a standalone therapy or together with chemotherapy, focused remedy or different established approaches.”
For now, RK-251 stays an experimental drug candidate. Its skill to activate primarily in most cancers cells is promising, however whether or not that interprets right into a protected and efficient therapy for sufferers will rely on additional analysis and human medical trials.
DISCLAIMER: This text is predicated on data from the general public area and/or the specialists we spoke to. At all times seek the advice of your well being practitioner earlier than beginning any routine.
